ClinicalTrials.gg
CompletedNCT02289456AboundPS2Updated Dec 7, 2018Results posted

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

A Phase 2 interventional study of nab-Paclitaxel and Carboplatin in Carcinoma, Non-Small-Cell Lung, sponsored by Celgene. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 11 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
30th of 47
40 · median 64
Started
2015
with 6 others
Phase 2
26 of 47
6 open now
Registered
20th of 47
by date
Lead sponsor
7 of 47
Celgene

Among the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, this one is the 30th largest by enrollment, is one of 7 that started in 2015, is one of 26 in phase 2, and was the 20th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing Albumin-Bound Paclitaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

4 cycles of induction treatment with nab-paclitaxel and carboplatin followed by nab-paclitaxel monotherapy for those subjects who are progression free at the end of 4 cycles.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Phase II, LOCALLY ADVANCED OR METASTATIC NON SMALL
  • CELL LUNG CANCER (NSCLC) AND AN
  • EASTERN COOPERATIVE ONCOLOGY GROUP
  • PERFORMANCE STATUS OF 2
  • (ABOUND.PS2)
  • LOCALLY ADVANCED OR METASTATIC NON SMALL
  • CELL LUNG CANCER (NSCLC) SUBJECTS THAT AE NOT CANDIDATES FOR RADIATION OR CURATIVE SURGERY
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General and Demographics

    1. Age ≥ 18 years of age at the time of signing the Form.
    2. Understand and voluntarily provide written consent to the Informed Consent Form prior to conducting any study related assessments/procedures.
    3. Able to adhere to the study visit schedule and other protocol requirements. Disease Specific
    4. or cytologically confirmed Stage IIIB or IV Non-Small Cell Lung Cancer.
    5. Radiographically documented at study entry per ( RECIST) v1.1.
    6. No prior anti-cancer therapy for the treatment of disease at the time of signing the ICF. treatment is permitted providing cytotoxic chemotherapy was completed 12 months prior to signing the ICF and without disease recurrence.
    7. (ANC) ≥ 1500 cells/mm3.
    8. ≥ 100,000 cells/mm3.
    9. (Hgb) ≥ 9 g/dL.
    10. (AST/serum glutamic oxaloacetic transaminase [SGOT]), alanine transaminase (ALT/serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 × (ULN) or ≤ 5.0 × ULN if liver metastases.
    11. Total ≤ 1.5 × ULN except in cases of Gilbert's disease and liver metastases.
    12. Serum creatinine ≤ 1.5 x ULN, or calculated ≥ 40 mL/min (if renal impairment is suspected 24-hour urine collection for measurement is required).
    13. Performance Status 2.
    14. Females of [defined as a sexually mature woman who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally for at least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months)] must:

      1. Have a negative pregnancy test Beta Human Chorionic Gonaditrophin(ß-hCG) as verified by the study doctor within 72 hours prior to starting study therapy.
      2. You must commit to complete abstinence from heterosexual contact, or agree to use medical doctor-approved throughout the study without interruption; while receiving study medication or for a longer period if required by local regulations.

        Male subjects must:

      3. practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 6 months following study drug discontinuation, even if he has undergone a successful vasectomy.

Exclusion criteria

Exclusion Criteria:

  • The presence of any of the following will exclude a subject from enrollment:

    1. Evidence of active , including (prior evidence of brain metastasis are permitted only if treated and stable and off therapy for at least 21days prior to signing ICF). MRI of the brain (or CT scan w/contrast) is preferred for diagnosis.
    2. History of leptomeningeal disease.
    3. Only evidence of disease is non-measurable.
    4. Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per Criteria for Adverse Events () v4.0).
    5. Subject has received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting product (IP), and/or from whom ≥ 30% of the bone marrow was irradiated. Prior radiation therapy to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed.
    6. Venous thromboembolism within 1 month prior to signing ICF.
    7. Current congestive heart failure ( Class II-IV).
    8. History of the following within 6 months prior to first administration of investigational product: a myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, New York Heart Association (NYHA) Class III-IV heart failure, uncontrolled hypertension, cardiac dysrhythmia or clinically significant abnormality, cerebrovascular accident, , or seizure disorder.
    9. Subject has a known infection with or C, or history of (HIV) infection, or subject receiving or myelosuppressive medications that would in the opinion of the investigator, increase the risk of serious neutropenic complications.
    10. Subject has an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment.
    11. History of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, or pulmonary pneumonitis.
    12. Treatment with any investigational product within 28 days prior to signing the ICF.
    13. History of or suspected allergy to nab-paclitaxel, carboplatin and human albumin or any other platinum-based therapy.
    14. Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices.
    15. Any other clinically significant medical condition, psychiatric illness, and/or organ dysfunction that will interfere with the administration of the therapy according to this protocol or which, in the views of investigator, preclude combination chemotherapy.
    16. Subject has any other within 5 years prior to signing the ICF. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (Tumor, node and (TNM) stage of T1a or T1b). All treatment should have been completed 6 months prior to signing ICF.
    17. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
    18. Any medical condition that confounds the ability to interpret data from the study. This includes subjects with known psychiatric disorders.
    19. Pregnant or breast-feeding females.
    20. Subjects with an PS other than 2
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    nab-Paclitaxel

    nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle • Carboplatin AUC = 5 mg\*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion.

    Drug: nab-Paclitaxel · Drug: Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).

    Treatment-emergent adverse events were defined as any adverse event (AE) or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the investigational product through 28 days after the last dose of IP. In addition, any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. A participant met the primary endpoint if: an AE was the reason for discontinuation as recorded in the electronic Case Report Form (eCRF) and the participant had no doses administered beyond Cycle 4. 95% confidence interval for the percentage was calculated using the Clopper Pearson method.

    Time frame: From date of the first dose of IP until 28 days after the last dose of IP during induction and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; maximum treatment duration during induction was 3.9 months

Secondary outcomes

  1. Percentage of Participants Who Discontinued Study Treatment During the Induction Period (Discontinuation Rate)

    Discontinuation Rate was measured as Percentage of Participants who Discontinued Study Treatment During the Induction Period

    Time frame: From date of the first dose of IP until 28 days after the last dose of IP during induction and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; maximum treatment duration during induction was 3.9 months

  2. Dose Intensity of Nab-Paclitaxel During the Entire Study

    Dose intensity for nab-paclitaxel during the entire study period was (mg/m\^2/week) = \[cumulative dose for nab-paclitaxel in mg/m\^2\] / \[nab-paclitaxel dosing period in weeks\]

    Time frame: From Day 1 of study treatment to end of study treatment; maximum treatment duration on study was 14.1 months

  3. Dose Intensity of Carboplatin During the Entire Study

    Dose intensity for carboplatin during the entire study period was (mg\*min/mL/week) = \[cumulative dose for carboplatin in mg\*min/mL\] / \[carboplatin dosing period in weeks\].

    Time frame: From Day 1 of study treatment to end of study treatment; maximum treatment duration on study was 14.1 months

  4. Percentage of Participants With Dose Reductions During the Entire Study

    A dose reduction occurs when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions are typically caused by clinically significant laboratory abnormalities and/or treatment emergent adverse events or toxicities.

    Time frame: From day 1 of IP until 28 days after the last dose of IP; maximum treatment duration was 14.1 months during the entire study

  5. Kaplan Meier Estimate of Progression-Free Survival (PFS)

    Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir

    Time frame: From Day 1 of study drug treatment to the date of disease progression; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months

  6. Percentage of Participants Who Achieved a Complete Response or Partial Response or Continued Stable Disease (Disease Control Rate)

    Disease control rate was defined as the percentage of participants who had continued stable disease, complete or partial response during the course of the study, according to RECIST v1.1 guidelines, as evaluated by the investigator. RECIST V1.1 criteria includes: - Complete Response is the disappearance of all target lesions; - Partial Response is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease; - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir

    Time frame: Response assessments were evaluated every 6 weeks; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months

  7. Kaplan Meier Estimate of Overall Survival (OS)

    Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.

    Time frame: From Day 1 of study treatment to death from any cause; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months

  8. Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST 1.1 Guidelines

    Overall tumor response is defined as the percentage of participants who achieved an objective confirmed CR (the disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions from baseline) according to RECIST V1.1 guidelines, compared with baseline where baseline was the last computed tomography (CT) scan obtained prior to or on Day 1 of study treatment.

    Time frame: Response assessments were evaluated every 2 cycles; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months

  9. Time to Response

    Time to response was defined as the time from Day 1 of study treatment to the first occurrence of response (CR or PR) according to RECIST v1.1 guidelines. RECIST V1.1 criteria includes: - A Complete Response (CR) is the disappearance of all target lesions; - A Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline

    Time frame: From Day 1 of study drug treatment to the date of first occurrence of CR or PR; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months

  10. Kaplan Meier Estimate of Duration of Response

    Duration of overall response was measured from the time measurement criteria were first met for CR (the disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions from baseline), whichever was first recorded, until the first date that recurrent disease or PD (at least a 20% increase in the sum of diameters of target lesions from nadir) was radiologically documented (taking as reference for PD the smallest measurements recorded on study). Median and 95% CI were estimated based on the Kaplan-Meier method.

    Time frame: From Day 1 of study drug treatment to the date of first occurrence of CR or PR; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months

  11. Number of Participants With TEAEs During the Induction and Monotherapy Periods

    Treatment-emergent adverse events were defined as any adverse event or serious adverse event that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. In addition, any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild l intervention/therapy required Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death.

    Time frame: From date of the first dose of IP until 28 days after the last IP dose and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; up to cutoff date of 24 Feb 2017; maximum treatment duration was 14.1 months

Other outcomes

  1. Percentage of Protocol Dose

    The percentage of protocol specified dose administered during the induction and monotherapy periods. Percentage of protocol dose = (dose intensity / protocol weekly dose) \* 100%; the protocol weekly dose of nab-paclitaxel is 66.67 mg/m2/week; the protocol weekly dose of carboplatin was 1.67 mg\*min/mL/week.

    Time frame: From Day 1 of study drug treatment to end of study drug treatment; up to clinical data cut-off date of 24 February 2017; ; maximum treatment duration was 14.1 months.

07

Results

Posted Apr 24, 2018
Limitations and caveats
Due to slower than expected enrollment, Celgene elected to end enrollment. The decision was not based on safety concerns; those enrolled continued treatment and survival follow-up until 24 February 2017.

Participant flow

This multicenter study was conducted in the United States (US) and enrolled participants at 7 sites.

Induction Period
Participant flow — Induction Period
MilestoneNab-Paclitaxel and Carboplatin
Started40
Treated population40
Completed16
Not completed24
Withdrew: Death2
Withdrew: Adverse event11
Withdrew: Progressive disease (pd)4
Withdrew: Symptomatic deterioration4
Withdrew: Withdrawal by subject2
Withdrew: Miscellaneous1
Monotherapy Period
Participant flow — Monotherapy Period
MilestoneNab-Paclitaxel and Carboplatin
Started16
Completed0
Not completed16
Withdrew: Death1
Withdrew: Adverse event1
Withdrew: Progressive disease (pd)8
Withdrew: Symptomatic deterioration1
Withdrew: Withdrawal by subject2
Withdrew: Study terminated by sponsor2
Withdrew: Miscellaneous1

Outcome measures

PrimaryPercentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).

Treatment-emergent adverse events were defined as any adverse event (AE) or serious adverse event (SAE) that occurred or worsened on or after the day of the first dose of the investigational product through 28 days after the last dose of IP. In addition, any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. A participant met the primary endpoint if: an AE was the reason for discontinuation as recorded in the electronic Case Report Form (eCRF) and the participant had no doses administered beyond Cycle 4. 95% confidence interval for the percentage was calculated using the Clopper Pearson method.

Time frame:
From date of the first dose of IP until 28 days after the last dose of IP during induction and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; maximum treatment duration during induction was 3.9 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).
Percentage of Participants(Induction Period) Nab-Paclitaxel and Carboplatin
Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs).27 (14.60 to 43.89)
SecondaryPercentage of Participants Who Discontinued Study Treatment During the Induction Period (Discontinuation Rate)

Discontinuation Rate was measured as Percentage of Participants who Discontinued Study Treatment During the Induction Period

Time frame:
From date of the first dose of IP until 28 days after the last dose of IP during induction and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; maximum treatment duration during induction was 3.9 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Treatment During the Induction Period (Discontinuation Rate)
Percentage of Participants(Induction Period) Nab-Paclitaxel and Carboplatin
Percentage of Participants Who Discontinued Study Treatment During the Induction Period (Discontinuation Rate)60.0
SecondaryDose Intensity of Nab-Paclitaxel During the Entire Study

Dose intensity for nab-paclitaxel during the entire study period was (mg/m\^2/week) = \[cumulative dose for nab-paclitaxel in mg/m\^2\] / \[nab-paclitaxel dosing period in weeks\]

Time frame:
From Day 1 of study treatment to end of study treatment; maximum treatment duration on study was 14.1 months
Reported as:
Mean · mg/m^2/week
Dose Intensity of Nab-Paclitaxel During the Entire Study
mg/m^2/weekNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Dose Intensity of Nab-Paclitaxel During the Entire Study52.173 ± 10.3066
SecondaryDose Intensity of Carboplatin During the Entire Study

Dose intensity for carboplatin during the entire study period was (mg\*min/mL/week) = \[cumulative dose for carboplatin in mg\*min/mL\] / \[carboplatin dosing period in weeks\].

Time frame:
From Day 1 of study treatment to end of study treatment; maximum treatment duration on study was 14.1 months
Reported as:
Mean · mg*min/mL/week
Dose Intensity of Carboplatin During the Entire Study
mg*min/mL/weekNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Dose Intensity of Carboplatin During the Entire Study1.170 ± 0.4673
SecondaryPercentage of Participants With Dose Reductions During the Entire Study

A dose reduction occurs when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions are typically caused by clinically significant laboratory abnormalities and/or treatment emergent adverse events or toxicities.

Time frame:
From day 1 of IP until 28 days after the last dose of IP; maximum treatment duration was 14.1 months during the entire study
Reported as:
Number · Percentage of Participants
Percentage of Participants With Dose Reductions During the Entire Study
Percentage of ParticipantsNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
nab-Paclitaxel32.5
Carboplatin27.5
SecondaryKaplan Meier Estimate of Progression-Free Survival (PFS)

Progression-free survival was defined as the time in months from day 1 of treatment to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by radiological assessment) or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. RECIST V1.1 criteria includes: - Complete Response (CR) is the disappearance of all target lesions; - Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease (PD); - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir

Time frame:
From Day 1 of study drug treatment to the date of disease progression; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
Reported as:
Median · months
Kaplan Meier Estimate of Progression-Free Survival (PFS)
monthsNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Kaplan Meier Estimate of Progression-Free Survival (PFS)4.40 (2.99 to 7.00)
SecondaryPercentage of Participants Who Achieved a Complete Response or Partial Response or Continued Stable Disease (Disease Control Rate)

Disease control rate was defined as the percentage of participants who had continued stable disease, complete or partial response during the course of the study, according to RECIST v1.1 guidelines, as evaluated by the investigator. RECIST V1.1 criteria includes: - Complete Response is the disappearance of all target lesions; - Partial Response is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease; - Progressive Disease is at least a 20% increase in the sum of diameters of target lesions from nadir

Time frame:
Response assessments were evaluated every 6 weeks; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved a Complete Response or Partial Response or Continued Stable Disease (Disease Control Rate)
Percentage of ParticipantsNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Percentage of Participants Who Achieved a Complete Response or Partial Response or Continued Stable Disease (Disease Control Rate)75.0 (58.80 to 87.31)
SecondaryKaplan Meier Estimate of Overall Survival (OS)

Overall survival was defined as the time in months between day 1 of treatment and death from any cause). Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact.

Time frame:
From Day 1 of study treatment to death from any cause; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
Reported as:
Median · months
Kaplan Meier Estimate of Overall Survival (OS)
monthsNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Kaplan Meier Estimate of Overall Survival (OS)7.66 (4.93 to 13.17)
SecondaryPercentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST 1.1 Guidelines

Overall tumor response is defined as the percentage of participants who achieved an objective confirmed CR (the disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions from baseline) according to RECIST V1.1 guidelines, compared with baseline where baseline was the last computed tomography (CT) scan obtained prior to or on Day 1 of study treatment.

Time frame:
Response assessments were evaluated every 2 cycles; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST 1.1 Guidelines
Percentage of participantsNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST 1.1 Guidelines30.0 (16.56 to 46.53)
SecondaryTime to Response

Time to response was defined as the time from Day 1 of study treatment to the first occurrence of response (CR or PR) according to RECIST v1.1 guidelines. RECIST V1.1 criteria includes: - A Complete Response (CR) is the disappearance of all target lesions; - A Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions from baseline

Time frame:
From Day 1 of study drug treatment to the date of first occurrence of CR or PR; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
Reported as:
Median · Months
Time to Response
MonthsNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Time to Response2.00 (1.2 to 5.7)
SecondaryKaplan Meier Estimate of Duration of Response

Duration of overall response was measured from the time measurement criteria were first met for CR (the disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions from baseline), whichever was first recorded, until the first date that recurrent disease or PD (at least a 20% increase in the sum of diameters of target lesions from nadir) was radiologically documented (taking as reference for PD the smallest measurements recorded on study). Median and 95% CI were estimated based on the Kaplan-Meier method.

Time frame:
From Day 1 of study drug treatment to the date of first occurrence of CR or PR; up to the clinical cut-off date of 24 February 2017; maximum treatment duration on study was 14.1 months
Reported as:
Median · Months
Kaplan Meier Estimate of Duration of Response
MonthsNab-Paclitaxel/Carboplatin Followed by Nab-Paclitaxel
Kaplan Meier Estimate of Duration of Response6.83 (2.10 to 11.24)
SecondaryNumber of Participants With TEAEs During the Induction and Monotherapy Periods

Treatment-emergent adverse events were defined as any adverse event or serious adverse event that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP. In addition, any SAE with an onset date more than 28 day after the last dose of IP that was assessed by the investigator as related to IP was considered a TEAE. The severity of AEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild l intervention/therapy required Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death.

Time frame:
From date of the first dose of IP until 28 days after the last IP dose and SAEs made known to the investigator any time thereafter that are suspected of being related to IP; up to cutoff date of 24 Feb 2017; maximum treatment duration was 14.1 months
Reported as:
Count of participants · Participants
Number of Participants With TEAEs During the Induction and Monotherapy Periods
ParticipantsInduction Period: Nab-Paclitaxel and/or CarboplatinMonotherapy Period: Nab-Paclitaxel
TEAE4014
Serious TEAE204
Grade 1/2 TEAE3914
Grade 3/4 TEAE307
Grade 3 or Higher TEAE307
Treatment-Related TEAE3812
Treatment-Related Serious TEAE130
TEAE With Action to Reduce/Interrupt IP253
Treatment-Related to Reduce or Interrupt IP222
TEAE with Action Taken to Withdraw IP111
Treatment-Related TEAE Action to Halt IP81
TEAE with Fatal Outcome10
Treatment-Related TEAE with Fatal Outcome00
Other pre-specifiedPercentage of Protocol Dose

The percentage of protocol specified dose administered during the induction and monotherapy periods. Percentage of protocol dose = (dose intensity / protocol weekly dose) \* 100%; the protocol weekly dose of nab-paclitaxel is 66.67 mg/m2/week; the protocol weekly dose of carboplatin was 1.67 mg\*min/mL/week.

Time frame:
From Day 1 of study drug treatment to end of study drug treatment; up to clinical data cut-off date of 24 February 2017; ; maximum treatment duration was 14.1 months.
Reported as:
Median · Percentage of Protocol Dose
Percentage of Protocol Dose
Percentage of Protocol DoseInduction Period: Nab-Paclitaxel and/or CarboplatinMonotherapy Period: Nab-Paclitaxel
nab-Paclitaxel82.620 (47.11 to 101.20)71.185 (46.32 to 101.61)
Carboplatin80.630 (19.59 to 110.31)NA (NA to NA)

Adverse events

Collected over From date of first dose of IP until 28 days after the last dose of IP and those SAEs made known to the Investigator at any time thereafter that are suspected of being related to IP: up to the clinical cut-off date of 24 February 2017.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction: Nab-Paclitaxel/Carboplatin6/40 (15%)20/40 (50%)40/40 (100%)
Monotherapy: Nab-Paclitaxel2/16 (12.5%)4/16 (25%)13/16 (81.3%)
Follow-Up Period16/31 (51.6%)0/31 (0%)0/31 (0%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventInduction: Nab-Paclitaxel/CarboplatinMonotherapy: Nab-PaclitaxelFollow-Up Period
PneumoniaInfections and infestations3/402/160/31
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/400/160/31
AstheniaGeneral disorders1/401/160/31
AtaxiaNervous system disorders0/401/160/31
HeadacheNervous system disorders0/401/160/31
Febrile neutropeniaBlood and lymphatic system disorders2/400/160/31
Cardiac arrestCardiac disorders2/400/160/31
DehydrationMetabolism and nutrition disorders2/400/160/31
DyspnoeaRespiratory, thoracic and mediastinal disorders2/400/160/31
Deep vein thrombosisVascular disorders2/400/160/31
Most frequent other events
Showing 10 of 76
Most frequent other events
EventInduction: Nab-Paclitaxel/CarboplatinMonotherapy: Nab-PaclitaxelFollow-Up Period
NauseaGastrointestinal disorders21/401/160/31
FatigueGeneral disorders18/404/160/31
AnaemiaBlood and lymphatic system disorders17/405/160/31
NeutropeniaBlood and lymphatic system disorders13/402/160/31
Decreased appetiteMetabolism and nutrition disorders10/400/160/31
ConstipationGastrointestinal disorders9/401/160/31
AstheniaGeneral disorders9/401/160/31
DehydrationMetabolism and nutrition disorders9/401/160/31
AlopeciaSkin and subcutaneous tissue disorders9/400/160/31
ThrombocytopeniaBlood and lymphatic system disorders8/400/160/31

Baseline characteristics

The treated population consisted of all participants who received at least 1 dose of investigational product (IP).

Age, Continuous
Age, Continuous(Years)(Induction Period) Nab-Paclitaxel and Carboplatin
Mean67.4 ± 9.80
Sex: Female, Male
Sex: Female, Male(Participants)(Induction Period) Nab-Paclitaxel and Carboplatin
Female16
Male24
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)(Induction Period) Nab-Paclitaxel and Carboplatin
Hispanic or Latino3
Not Hispanic or Latino37
Race
Race(Participants)(Induction Period) Nab-Paclitaxel and Carboplatin
White37
Black3
Physician Reported Eastern Cooperative Oncology Group (ECOG) Performance Status at Screening
Physician Reported Eastern Cooperative Oncology Group (ECOG) Performance Status at Screening(Participants)(Induction Period) Nab-Paclitaxel and Carboplatin
0 = Fully Active0
1 = Restricted in Physical Activity; Ambulatory0
2 = Ambulatory and Capable of All Self-care40
3 = Capable of Only Limited Self-care0
4 = Completely Disabled.0
5 = Dead0
Histology
Histology(Participants)(Induction Period) Nab-Paclitaxel and Carboplatin
Squamous15
Non-squamous25
Stage of Disease at Enrollment
Stage of Disease at Enrollment(Participants)(Induction Period) Nab-Paclitaxel and Carboplatin
Stage 00
Stage I0
Stage II0
Stage IIIb1
Stage IV39
Number of Participants with Prior Systemic Anticancer Therapies
Number of Participants with Prior Systemic Anticancer Therapies(Participants)(Induction Period) Nab-Paclitaxel and Carboplatin
Number3
08

Study locations

8 sites
  • University Cancer Institute
    Boynton Beach, Florida 33426, United States
  • Ochsner Clinic Nephrology
    New Orleans, Louisiana 70121, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • University of RochesterJames P. Wilmont Cancer Center
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15232, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Feb 2017, 21 months.

Results were first posted in Apr 2018, 1 year 2 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2014
First posted
Nov 13, 2014
StartActual
Apr 28, 2015
Primary completionActual
Feb 22, 2017
CompletionActual
Feb 22, 2017
Results first posted
Apr 24, 2018
Last update
Dec 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02289456
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 13, 2014
Start date
Apr 28, 2015
Primary completion
Feb 22, 2017
Completion
Feb 22, 2017
Results posted
Apr 24, 2018
Last update
Dec 7, 2018

Study contacts

Francois Lafleur, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Carboplatin

Start the discussion